Persist AI, a leader in AI-driven robotics for pharmaceutical formulation and CMC (Chemistry, Manufacturing, and Controls), today announced the launch of its innovative Cloud Lab platform. Backed by an oversubscribed $12 million Series A round led by Spero Ventures, Persist AI’s platform enables remote development and testing of drug formulations, drastically reducing development time and material consumption compared to traditional methods.
Transforming Formulation with AI and Robotics
Predicting Optimal Formulations
Using advanced AI models, Persist AI predicts formulation recipes and performance, enabling pharmaceutical companies to develop new drugs faster. A recent client project demonstrated the power of the platform by identifying an optimal long-acting injectable formulation in just two months, accelerating what traditionally takes a year or more.
Remote Robotic Lab Testing
Persist’s Cloud Lab allows scientists to remotely build and test formulations using state-of-the-art robotic facilities. Miniaturized testing systems require only milliliters of liquid and milligrams of materials, preserving valuable drug substances and increasing throughput significantly.
Advantages of Persist AI’s Cloud Lab
- Speed & Efficiency: Tests up to 700 formulations in two months versus the industry average of 10–15 per month.
- Material Savings: Uses a fraction of materials required by conventional testing, lowering costs and waste.
- Wide Modalities Support: Supports peptides, small molecules, antibodies, and oligonucleotides, catering to top pharma clients and biotechs alike.
- Scalable & Remote Access: Enables global pharmaceutical companies to accelerate drug formulation from anywhere.
Series A Funding to Accelerate Growth
The $12 million Series A funding will support Persist AI in:
- Building GMP manufacturing systems for long-acting injectables with Nivagen Pharmaceuticals.
- Expanding robotic lab capacity and data sets to improve AI models.
- Broadening formulation types the platform can predict and test.
Persist is actively seeking pharma partners for co-development of drug products, AI training data, and robotic platforms.
Persist AI’s Cloud Lab marks a significant leap forward in pharmaceutical formulation development by combining cutting-edge AI and robotics. This innovation promises to speed drug development timelines, reduce costs, and conserve precious materials — ultimately accelerating the path from molecule discovery to patient-ready therapeutics.
